Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice

mBio

Volumn 6, Issue 2, 2015, Pages

  Wohlbold, Teddy John ^a   Nachbagauer, Raffael ^a,b   Xu, Haoming ^a   Tan, Gene S ^a   Hirsh, Ariana ^a   Brokstad, Karl A ^c   Cox, Rebecca J ^c,d   Palese, Peter ^a   Krammer, Florian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; RECOMBINANT NEURAMINIDASE; UNCLASSIFIED DRUG; NA PROTEIN, INFLUENZA A VIRUS; NA PROTEIN, INFLUENZA B VIRUS; RECOMBINANT VACCINE; SIALIDASE; VIRAL PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIRUS ISOLATION; VIRUS STRAIN; WESTERN BLOTTING; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; HETEROLOGOUS IMMUNITY; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS;

INFLUENZA B VIRUS; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, HETEROLOGOUS; INFLUENZA VACCINES; MICE; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 84929494198     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02556-14     Document Type: Article

References (42)

1. Jayasundara K, Soobiah C, Thommes E, Tricco AC, Chit A. 2014. Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis. BMC Infect Dis 14:670. http://dx.doi.org/10.1186/s12879-014-0670-5.
2. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M. 2013. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and metaanalysis. BMC Med 11:153. http://dx.doi.org/10.1186/1741-7015-11-153.
3. De Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. 2000. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61: 94-99. http://dx.doi.org/10.1002/(SICI)1096-9071(200005)61:1_94::AID-JMV15_3.0.CO;2-C.
4. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667-671. http://dx.doi.org/10.1038/nature06890.
5. Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, McClain MT, Denny TN, Chen X, Munshaw S, Marshall DJ, Whitesides JF, Drinker MS, Amos JD, Gurley TC, Eudailey JA, Foulger A, DeRosa KR, Parks R, Meyerhoff RR, Yu JS, Kozink DM, Barefoot BE, Ramsburg EA, Khurana S, Golding H, Vandergrift NA, Alam SM, Tomaras GD, Kepler TB, Kelsoe G, Liao HX, Haynes BF. 2011. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One 6:e25797. http://dx.doi.org/10.1371/journal.pone.0025797.
6. Margine I, Hai R, Albrecht RA, Obermoser G, Harrod AC, Banchereau J, Palucka K, García-Sastre A, Palese P, Treanor JJ, Krammer F. 2013. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol 87:4728-4737. http://dx.doi.org/10.1128/JVI.03509-12.
7. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521-530. http://dx.doi.org/10.1016/j.coviro.2013.07.007.
8. Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine 21:1776-1779. http://dx.doi.org/10.1016/S0264-410X(03)00071-9.
9. Wohlbold TJ, Krammer F. 2014. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6:2465-2494. http://dx.doi.org/10.3390/v6062465.
10. Schulman JL, Khakpour M, Kilbourne ED. 1968. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 2:778-786.
11. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Matsuo K, Kurata T, Tamura S. 2000. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18:3214-3222. http://dx.doi.org/10.1016/S0264-410X(00)00149-3.
12. Sylte MJ, Hubby B, Suarez DL. 2007. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 25:3763-3772. http://dx.doi.org/10.1016/j.vaccine.2007.02.011.
13. Rockman S, Brown LE, Barr IG, Gilbertson B, Lowther S, Kachurin A, Kachurina O, Klippel J, Bodle J, Pearse M, Middleton D. 2013. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol 87:3053-3061. http://dx.doi.org/10.1128/JVI.02434-12.
14. Van Reeth K, Braeckmans D, Cox E, Van Borm S, van den Berg T, Goddeeris B, De Vleeschauwer A. 2009. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus. Vaccine 27:6330-6339. http://dx.doi.org/10.1016/j.vaccine.2009.03.021.
15. Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC. 2013. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol 87:9290-9300. http://dx.doi.org/10.1128/JVI.01203-13.
16. Easterbrook JD, Schwartzman LM, Gao J, Kash JC, Morens DM, Couzens L, Wan H, Eichelberger MC, Taubenberger JK. 2012. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432:39-44. http://dx.doi.org/10.1016/j.virol.2012.06.003.
17. Chen Z, Kim L, Subbarao K, Jin H. 2012. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 30:2516-2522. http://dx.doi.org/10.1016/j.vaccine.2012.01.090.
18. Halbherr SJ, Ludersdorfer TH, Ricklin M, Locher S, Berger Rentsch M, Summerfield A, Zimmer G. 2015. Biological and protective properties of immune sera directed to influenza virus neuraminidase. J Virol 89: 1550-1563. http://dx.doi.org/10.1128/JVI.02949-14.
19. He B, Chang H, Liu Z, Huang C, Liu X, Zheng D, Fang F, Sun B, Chen Z. 2014. Infection of influenza virus neuraminidase-vaccinated mice with homologous influenza virus leads to strong protection against heterologous influenza viruses. J Gen Virol 95:2627-2637. http://dx.doi.org/10.1099/vir.0.067736-0.
20. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. 1974. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 129:411-420. http://dx.doi.org/10.1093/infdis/129.4.411.
21. Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC. 1973. Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J 49:159-163. http://dx.doi.org/10.1136/pgmj.49.569.159.
22. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW, Ogra PL. 1987. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol 138:3010-3013.
23. Martinet W, Saelens X, Deroo T, Neirynck S, Contreras R, Min Jou W, Fiers W. 1997. Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. Eur J Biochem 247:332-338. http://dx.doi.org/10.1111/j.1432-1033.1997.00332.x.
24. Deroo T, Jou WM, Fiers W. 1996. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 14:561-569. http://dx.doi.org/10.1016/0264-410X(95)00157-V.
25. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. 2010. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 45: 226-234. http://dx.doi.org/10.1007/s12033-010-9268-3.
26. Margine I, Palese P, Krammer F. 2013. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp 81: e51112. http://dx.doi.org/10.3791/51112.
27. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. 2008. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol 82: 10493-10501. http://dx.doi.org/10.1128/JVI.00959-08.
28. Eriksson JC, Cox RJ, Szyszko E, Davidsson A, Brokstad KA. 2007. Local and systemic cytokine and chemokine responses after parenteral influenza vaccination. Influenza Other Respir Viruses 1:139-146. http://dx.doi.org/10.1111/j.1750-2659.2007.00019.x.
29. Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. 2014. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 88:13260-13268. http://dx.doi.org/10.1128/JVI.02133-14.
30. Johansson BE, Moran TM, Kilbourne ED. 1987. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci U S A 84:6869-6873. http://dx.doi.org/10.1073/pnas.84.19.6869.
31. Johansson BE, Kilbourne ED. 1993. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 67:5721-5723.
32. Johansson BE, Kilbourne ED. 1994. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc Natl Acad Sci U S A 91:2358-2361. http://dx.doi.org/10.1073/pnas.91.6.2358.
33. Yang X, Steukers L, Forier K, Xiong R, Braeckmans K, Van Reeth K, Nauwynck H. 2014. A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus. PLoS One 9:e110026. http://dx.doi.org/10.1371/journal.pone.0110026.
34. Palese P, Shaw ML (ed). 2007. Fields’ virology. Lippincott Williams & Wilkins, Philadelphia, PA.
35. Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70:767-777.
36. Krammer F, Jul-Larsen A, Margine I, Hirsh A, Sjursen H, Zambon M, Cox RJ. 2014. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol 21: 1153-1163. http://dx.doi.org/10.1128/CVI.00272-14.
37. Harris A, Cardone G, Winkler DC, Heymann JB, Brecher M, White JM, Steven AC. 2006. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci U S A 103:19123-19127. http://dx.doi.org/10.1073/pnas.0607614103.
38. Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X. 2013. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res 100:567-574. http://dx.doi.org/10.1016/j.antiviral.2013.09.018.
39. Doyle TM, Li C, Bucher DJ, Hashem AM, Van Domselaar G, Wang J, Farnsworth A, She YM, Cyr T, He R, Brown EG, Hurt AC, Li X. 2013. A monoclonal antibody targeting a highly conserved epitope in influenza B neuraminidase provides protection against drug resistant strains. Biochem Biophys Res Commun 441:226-229. http://dx.doi.org/10.1016/j.bbrc.2013.10.041.
40. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4:e59. http://dx.doi.org/10.1371/journal.pmed.0040059.
41. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87:6542-6550. http://dx.doi.org/10.1128/JVI.00641-13.
42. Rolfes M, Blanton L, Brammer L, Smith S, Mustaquim D, Steffens C, Cohen J, Leon M, Chaves SS, Abd Elal AI, Gubareva L, Hall H, Wallis T, Villanueva J, Bresee J, Cox N, Finelli L. 2014. Update: influenza activity—United States, September 28-December 6, 2014.MMWRMorb Mortal Wkly Rep 63:1189-1194